Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Aldeyra Therapeutics (DE:137)
FRANKFURT:137
Aldeyra Therapeutics (137) Stock Price & Analysis
0 Followers
137 Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€1.37 - €11.13
Previous Close€3.66
Volume0.00
Average Volume (3M)766.00
Market Cap
€216.90M
Enterprise Value€231.58M
Total Cash (Recent Filing)$0.00
Total Debt (Recent Filing)$15.66M
Price to Earnings (P/E)N/A
Beta0.78
Next Earnings
May 02, 2024EPS Estimate
-€0.1Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding58,895,768
10 Day Avg. Volume237
30 Day Avg. Volume766
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)1.93
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)115.60
P/FCF Ratio57.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-6.64
Forecast
1Y Price Target
€8.87Price Target Upside142.61% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Aldeyra Therapeutics News
PremiumCompany Announcements
Aldeyra Therapeutics Unveils R&D Progress and Goals
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentAldeyra's positive clinical study results and plans for a new trial designed to satisfy FDA requirements hint at a promising future for its therapeutic pipeline.
Market PotentialWith a large potential market for ADX-629 targeting the prevalent mild to moderate atopic dermatitis, significant market share gains could be on the horizon.
Strategic PartnershipsThe potential for significant milestone payments and shared profits from a partnership with AbbVie serves as a strong incentive for Aldeyra's stock performance.
Bears Say
Clinical Trial ConcernsThe confounding part of the treatment was driven by a placebo group that got worse in an area of drug development where placebo patients generally get slightly better.
Drug Approval SetbackAldeyra received a CRL for the NDA of reproxalap in the treatment of dry eye disease (DED), which indicated that an additional study is required to demonstrate positive effect in the treatment of ocular symptoms.
Regulatory ChallengesThe FDA wants another trial to demonstrate control of symptoms for Reproxalap in DED, and the company has received a CRL.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.00% Insiders
0.00% Mutual Funds
1.27% Other Institutional Investors
98.73% Public Companies and
Individual Investors
137 FAQ
What was Aldeyra Therapeutics’s price range in the past 12 months?
Aldeyra Therapeutics lowest stock price was €1.37 and its highest was €11.13 in the past 12 months.
What is Aldeyra Therapeutics’s market cap?
Currently, no data Available
When is Aldeyra Therapeutics’s upcoming earnings report date?
Aldeyra Therapeutics’s upcoming earnings report date is May 02, 2024 which is in 6 days.
How were Aldeyra Therapeutics’s earnings last quarter?
Aldeyra Therapeutics released its earnings results on Mar 07, 2024. The company reported -€0.075 earnings per share for the quarter, beating the consensus estimate of -€0.104 by €0.029.
Is Aldeyra Therapeutics overvalued?
According to Wall Street analysts Aldeyra Therapeutics’s price is currently Undervalued.
Does Aldeyra Therapeutics pay dividends?
Aldeyra Therapeutics does not currently pay dividends.
What is Aldeyra Therapeutics’s EPS estimate?
Aldeyra Therapeutics’s EPS estimate is -€0.1.
How many shares outstanding does Aldeyra Therapeutics have?
Currently, no data Available
What happened to Aldeyra Therapeutics’s price movement after its last earnings report?
Aldeyra Therapeutics reported an EPS of -€0.075 in its last earnings report, beating expectations of -€0.104. Following the earnings report the stock price went down -0.558%.
Which hedge fund is a major shareholder of Aldeyra Therapeutics?
Among the largest hedge funds holding Aldeyra Therapeutics’s share is Perceptive Advisors LLC. It holds Aldeyra Therapeutics’s shares valued at 30M.
---
Aldeyra Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€8.87 (142.61% Upside)
€8.87 (142.61% Upside)
Blogger Sentiment
Bullish
DE:137 Sentiment 85%
Sector Average 70%
Sector Average 70%
Insider Transactions
Bought Shares
Worth $2.7M over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-60.97%
12-Months-Change
Fundamentals
Return on Equity
-27.73%
Trailing 12-Months
Asset Growth
-18.18%
Trailing 12-Months
Company Description
Aldeyra Therapeutics
Aldeyra Therapeutics, Inc. operates as a biotechnology company. It primarily focuses on the development of new products for immune-mediated, inflammatory, orphan and other diseases that are thought to be caused in part by naturally occurring toxic chemical species known as free aldehydes. The company was founded by Thomas A. Jordan and John E. Dowling on August 13, 2004 and is headquartered in Lexington, MA.
---
137 Company Deck
---
137 Earnings Call
Q4 2023
0:00 / 0:00
---
137 Stock 12 Months Forecast
Average Price Target
€8.87
▲(142.61% Upside)
Technical Analysis
Aldeyra Therapeutics
―
Protagonist Therapeutics
―
Clearside Biomedical
―
Crispr Therapeutics AG
―
Arrowhead Pharmaceuticals
―
Best Analysts Covering 137
1 Year
1 Year Success Rate
7/12 ratings generated profit
1 Year Average Return
+40.99%
initiated a buy rating 24 days ago
Copying Matthew Caufield's trades and holding each position for 1 Year would result in 58.33% of your transactions generating a profit, with an average return of +40.99% per trade.
---